MHAN Manhattan Pharmaceuticals Inc. featured news, full reports, and detailed charts
Manhattan Pharmaceuticals Inc. (MHAN/MHAN.OB) Wrap Up:
Manhattan Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of pharmaceutical therapies in the United States. Its product candidates under development includes Hedrin, a non-insecticide treatment for pediculosis; Topical PTH (1-34) for the treatment of psoriasis; Altoderm, a topical cromolyn sodium for the treatment of pruritus associated with dermatologic conditions, such as atopic dermatitis; and Altolyn, an oral tablet cromolyn sodium for the treatment of mastocytosis. Manhattan Pharmaceuticals, Inc. was founded in 2001 and is based in New York, New York.www.manhattanpharma.com
3 Employees
Founded in 2001
Manhattan Pharmaceuticals Inc. (MHAN:OTC Bulletin Board Market)
LAST $0.07 USD
CHANGE TODAY -0.0005 -0.67%
VOLUME 62.5K
As of 2:33 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Manhattan Pharmaceuticals Inc. (MHAN)
|
OPEN
$0.07
|
PREVIOUS CLOSE
$0.08
|
|
|
DAY HIGH
$0.07
|
DAY LOW
$0.07
|
|
|
52 WEEK HIGH
06/15/09 - $0.15
|
52 WEEK LOW
12/24/08 - $0.0040
|
|
|
MARKET CAP
5.3M
|
AVERAGE VOLUME 3 mo
144.5K
|
|
|
DILUTED EPS TTM
$-0.04
|
SHARES OUTSTANDING
70.6M
|
|
|
MHAN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MHAN Top Compensated Officers
Mr. Michael G. McGuinness
Chief Operating Officer, Chief Financial Offi...
Age: 55
Total Annual Compensation: $263.8K
Mr. Douglas Abel
Chairman and Consultant
Age: 47
Total Annual Compensation: $338.8K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Manhattan Pharmaceuticals Inc. (MHAN)
Manhattan Pharmaceuticals Inc., Annual General Meeting, Nov 30, 2009
10/29/2009
Manhattan Pharmaceuticals Inc., Annual General Meeting, Nov 30, 2009, at 10:00 US Eastern Time. Location: Lowenstein Sandler PC at 65 Livingston Avenue, Roseland, NJ 07068, United States. Agenda: To amend Certificate of Incorporation to increase the number of authorized shares of Common Stock from 300,000,000 to 500,000,000 to ensure that will have an adequate number of authorized and unissued shares of Common Stock available for future issuance; to elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; to amend the Company's 2003 Stock Option Plan to increase the number of shares available for issuance thereunder from 10,400,000 to 15,000,000; to ratify the appointment of J.H. Cohn LLP as independent registered public accounting firm for the year ending December 31, 2009; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.
Manhattan Pharmaceuticals to Amend Certificate of Incorporation
10/29/2009
At the AGM of Manhattan Pharmaceuticals Inc. to held on November 30, 2009, to amend Certificate of Incorporation to increase the number of authorized shares of Common Stock from 300,000,000 to 500,000,000 to ensure that will have an adequate number of authorized and unissued shares of Common Stock available for future issuance.
Manhattan Pharmaceuticals Inc. Announces Management and Executive Changes
06/18/2009
Manhattan Pharmaceuticals Inc. announced that effective June 16, 2009, Douglas Abel was appointed Chairman of the Manhattan Pharmaceuticals Board of Directors and stepped down from his positions as Chief Executive Officer and President. In addition to his role as Chairman of the Board, Mr. Abel has been retained as a consultant to the company and he will continue to work toward securing FDA approval and a commercialization and marketing partner for Hedrin in both the United States and Canada. Michael G. McGuinness, Chief Operating and Financial Officer, will assume day-to-day leadership responsibilities and Mary Spellman, M.D., a consultant to the company, will remain as Head of Dermatology and Drug Development.
MHAN Competitors
| Company | Last | Change | |
| No competitor information is available for MHAN. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | MHAN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
MHAN |
||
|
MHAN transactions
| Type Date |
Target |
|
Private Placement
October 28, 2009 |
-- |
More Recent News About Manhattan Pharmaceuticals Inc.
More news for MHAN
MANHATTAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion of our results of operations and financial condition in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2008 (the "Annual Report") and our financial statements for the nine month period ended September 30, 2009 included elsewhere in this report. We were incorporated in Delaware in 1993 under the name "Atlantic Pharmaceuticals, Inc." and, in March 2000, we changed our name to "Atlantic Technology Ventures, Inc." In 2003, we completed a "reverse acquisition" of privately held "Manhattan Research Development, Inc". In connection with this transaction, we also changed our name to "Manhattan Pharmaceuticals, Inc." From an accounting perspective, the accounting acquirer is considered to be Manhattan Research Development, Inc. and accordingly, the historical financial statements are those of Manhattan Research Development, Inc. During 2005 we merged with Tarpan Therapeutics, Inc. ("Tarpan"). Tarpan was a privately held New York based biopharmaceutical company developing dermatological therapeutics. Through the merger, we acquired Tarpan's primary product candidate, Topical PTH (1-34) for the treatment of psoriasis. In consideration for their shares of Tarpan's capital stock, the stockholders of Tarpan received an aggregate of approximately 10,731,000 shares of our common stock, representing approximately 20% of our then outstanding common shares. This transaction was accounted for as a purchase of Tarpan by the Company. We are a specialty healthcare product company focused on developing and commercializing pharmaceutical treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing th...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events, Financial Sta
Item 3.02 Unregistered Sales of Equity Securities On October 28, 2009, Manhattan Pharmaceuticals, Inc. (the "Company") entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which it sold a 12% Original Issue Discount Senior Subordinated Convertible Debenture with a stated value of $400,000 (the "Debenture") and a warrant (the "Warrant" and, together with the Debenture, the "Securities") to purchase 2,222,222 shares of the Company's common stock, par value $.001 par value per share ("Common Stock"). The Debenture is convertible into shares of Common Stock at an initial conversion price of $0.09 per share, subject to adjustment, or, in the event the Company issues new securities in connection with a financing the Debenture may be converted into such new securities at a conversion price equal to the purchase price paid by the purchasers of such new securities. The Company may also, in its sole discretion, elect to pay interest due under the Debenture quarterly in shares of Common Stock provided such shares are subject to an effective registration statement. The Debenture is subordinated to the Company's outstanding 12% Senior Secured Promissory Notes in the principal amount of $1,725,000. The Warrant is exercisable at an exercise price of $0.11 per share, subject to adjustment, prior to October 28, 2014. A copy of the Subscription Agreement, Debenture and Warrant are filed herewith as Exhibits 10.1, 10.2 and 10.3, respectively. The purchaser of the Securities represented that it was an "accredited investor," as that term is defined in Rule 501(a) of Regulation D under the Securities Act, and the sale of the Securities was made in reliance on exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933, as amended. In connection with the issuance of the Securities, the Company issued warrants to purchase an aggregrate of 222,222 shares of Common Stock at an exercise pric...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Financials
PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue - - - - Cost of Revenue - - - - Gross Profit - - - - Operating ExpensesResearch Development7 45 (62)499 Selling General and Administrative471 512 10 885 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(477)(557)52 (1,384)Income from Continuing OperationsTotal Other Income/Expenses Net(685)57 121 (100)Earnings Before Interest And Taxes(1,258)(636)173 (1,376)Interest Expense135 125 46 19 Income Before Tax(1,392)(762)127 (1,394)Income Tax Expense - - - - Minority Interest - - - - Net Income From Continuing Ops(1,392)(762)127 (1,394)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - ...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion of our results of operations and financial condition in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2008 (the "Annual Report") and our financial statements for the six month period ended June 30, 2009 included elsewhere in this report. We were incorporated in Delaware in 1993 under the name "Atlantic Pharmaceuticals, Inc." and, in March 2000, we changed our name to "Atlantic Technology Ventures, Inc." In 2003, we completed a "reverse acquisition" of privately held "Manhattan Research Development, Inc". In connection with this transaction, we also changed our name to "Manhattan Pharmaceuticals, Inc." From an accounting perspective, the accounting acquirer is considered to be Manhattan Research Development, Inc. and accordingly, the historical financial statements are those of Manhattan Research Development, Inc. During 2005 we merged with Tarpan Therapeutics, Inc. ("Tarpan"). Tarpan was a privately held New York based biopharmaceutical company developing dermatological therapeutics. Through the merger, we acquired Tarpan's primary product candidate, Topical PTH (1-34) for the treatment of psoriasis. In consideration for their shares of Tarpan's capital stock, the stockholders of Tarpan received an aggregate of approximately 10,731,000 shares of our common stock, representing approximately 20% of our then outstanding common shares. This transaction was accounted for as a purchase of Tarpan by the Company. We are a specialty healthcare product company focused on developing and commercializing pharmaceutical treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing the tech...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
Show all filings for MANHATTAN PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for MANHATTAN PHARMACEUTICALS INC 22-Jun-2009Change in Directors or Principal Officers, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informa...Click here to read the whole Article (external link)
Manhattan Pharmaceuticals Provides Corporate Update on Hedrin and Management Restructuring
NEW YORK, June 18, 2009 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN - News) today provided an update on its ongoing development programs. The Company also announced it has initiated a management restructuring that is intended to extend the Company's resources and allow it to continue working toward its near-term corporate objectives and to maximize the value of its assets. Hedrin(tm): Lead Product for the Treatment of Pediculosis (head lice)Hedrin is a next generation, non-pesticide treatment for head lice and is currently being developed as a 1-hour head lice treatment by and through a joint venture with Nordic Biotech. Hedrin was designated as a Class III medical device by the Food and Drug Administration ("FDA"), and we expect that the joint venture will have to complete a clinical study in order to obtain a product approval. The joint venture has requested a meeting with the FDA to confirm a study is necessary and to determine the trial design and the number of patients required. We expect that the joint venture will commence a clinical study shortly after receiving FDA feedback.In order to maximize the commercial value of Hedrin, the joint venture is seeking a marketing and distribution partner with a strong, established presence in the relevant markets. Under its management agreement with the joint venture, Manhattan Pharmaceuticals, on behalf of the joint venture, intends to secure a commercialization and marketing partner for Hedrin and discussions are currently ongoing with potential ...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion of our results of operations and financial condition in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2008 (the "Annual Report") and our financial statements for the three month period ended March 31, 2009 included elsewhere in this report. We were incorporated in Delaware in 1993 under the name "Atlantic Pharmaceuticals, Inc." and, in March 2000, we changed our name to "Atlantic Technology Ventures, Inc." In 2003, we completed a "reverse acquisition" of privately held "Manhattan Research Development, Inc". In connection with this transaction, we also changed our name to "Manhattan Pharmaceuticals, Inc." From an accounting perspective, the accounting acquirer is considered to be Manhattan Research Development, Inc. and accordingly, the historical financial statements are those of Manhattan Research Development, Inc. During 2005 we merged with Tarpan Therapeutics, Inc. ("Tarpan"). Tarpan was a privately held New York based biopharmaceutical company developing dermatological therapeutics. Through the merger, we acquired Tarpan's primary product candidate, Topical PTH (1-34) for the treatment of psoriasis. In consideration for their shares of Tarpan's capital stock, the stockholders of Tarpan received an aggregate of approximately 10,731,000 shares of our common stock, representing approximately 20% of our then outstanding common shares. This transaction was accounted for as a purchase of Tarpan by the Company. We are a specialty healthcare product company focused on developing and commercializing pharmaceutical treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing the t...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Overview We were incorporated in Delaware in 1993 under the name "Atlantic Pharmaceuticals, Inc." and, in March 2000, we changed our name to "Atlantic Technology Ventures, Inc." In 2003, we completed a "reverse acquisition" of privately held "Manhattan Research Development, Inc". In connection with this transaction, we also changed our name to "Manhattan Pharmaceuticals, Inc." From an accounting perspective, the accounting acquirer is considered to be Manhattan Research Development, Inc. and accordingly, the historical financial statements are those of Manhattan Research Development, Inc. During 2005 we merged with Tarpan Therapeutics, Inc. ("Tarpan"). Tarpan was a privately held New York based biopharmaceutical company developing dermatological therapeutics. Through the merger, we acquired Tarpan's primary product candidate, Topical PTH (1-34) for the treatment of psoriasis. In consideration for their shares of Tarpan's capital stock, the stockholders of Tarpan received an aggregate of approximately 10,731,000 shares of our common stock, representing approximately 20% of our then outstanding common shares. This transaction was accounted for as a purchase of Tarpan by the Company. We are a specialty healthcare product company focused on developing and commercializing pharmaceutical treatments for underserved patient populations. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding their research and development and eventually either bringing the technologies to market or out-licensing. In the short term we are focusing our efforts on the commercialization of the two product candidates we currently have in development: HedrinTM, through the Hedrin JV, a novel, non-insecticide treatment of pediculitis (head lice) and a topical product for the treatmen...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 8-K, Unregistered Sale of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities As previously disclosed on a Current Report on Form 8-K filed on November 25, 2008, Manhattan Pharmaceuticals, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated November 19, 2008 with the investors set forth on Exhibit A-1 and Exhibit A-2 thereto, as amended from time to time (the "Investors"), pursuant to which it sold 207 units (each a "Unit" and collectively, the "Units") with each Unit consisting of (i) a 12% Senior Secured Note Promissory Note in the principal amount of $5,000 (each a "Note", and collectively, the "Notes") and (ii) a warrant to purchase up to 166,667 shares of the Company's common stock ("Common Stock") at an exercise price of $.09 per share which expire on December 31, 2013 (each a "Warrant" and collectively, the "Warrants). On December 23, 2008, the Company completed a second closing (the "Second Closing") under the terms of the Securities Purchase Agreement. At the Second Closing the Company sold an additional 56 Units. On February 3, 2009, the Company completed its final closing (the "Final Closing") under the terms of the Securities Purchase Agreement. At the Final Closing the Company sold an additional 82 Units. All of the Investors represented that they were "accredited investors," as that term is defined in Rule 501(a) of Regulation D under the Securities Act, and the sale of the Units was made in reliance on exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933, as amended. In connection with the Final Closing, the Company issued a warrant to purchase 2,050,004 shares of Common Stock at an exercise price of $.09 per share to its placement agent (the "Placement Agent Warrant") as additional compensation for its services. The Company did not use any form of advertising or gen...Click here to read the whole Article (external link)
MANHATTAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
Show all filings for MANHATTAN PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for MANHATTAN PHARMACEUTICALS INC 27-Jan-2009Regulation FD Disclosure Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes...Click here to read the whole Article (external link)
Would you like to leave a comment about Manhattan Pharmaceuticals Inc. MHAN/MHAN.OB
Find out what social network information about Manhattan Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Manhattan Pharmaceuticals Inc. there is more great information available at Realpennies.com